Researchers at the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health reported interim results from a Phase 1 trial of a dual vaccine targeting Lassa fever and rabies. The study, published in Nature Medicine, evaluated an adjuvanted inactivated rabies virus-vectored Lassa virus vaccine in healthy adults. The team reported the vaccine was safe and induced immune responses against both viruses, with the investigators arguing the combined product could reduce the need for separate vaccination programs and streamline delivery in settings where both diseases co-circulate. The World Health Organization has identified Lassa virus as a public health threat in western Africa and prioritized Lassa fever research, while rabies remains almost universally fatal once symptoms develop. The trial’s interim findings support further clinical development if efficacy is confirmed. For the vaccine industry, combining targets into one product can matter operationally for cold-chain planning and outbreak response, particularly in regions with limited healthcare infrastructure.